DBV Technologies (ADR) (DBVT)
Develops an investigational skin patch for peanut allergy using epicutaneous immunotherapy.
Something off on this page? Send us feedback.
Develops the investigational Viaskin Peanut Patch, a skin-delivered immunotherapy candidate for peanut allergy. The business is concentrated on clinical development and a prospective U.S. launch, contingent on BLA submission and FDA review.
Develops Viaskin Peanut Patch, an investigational treatment candidate for peanut allergy based on epicutaneous immunotherapy, which delivers biologically active compounds through intact skin. The business is concentrated on this program rather than a marketed product portfolio, with clinical development focused on young children.
Operates from France with North American operations while building clinical, regulatory, and commercial capabilities for a prospective U.S. launch. Its near-term plan depends on completing the Biologics License Application package for FDA review; the therapies remain unapproved, and submission timing reflects FDA feedback on existing CMC and biostatistical datasets.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 18, 2025 | H.C. Wainwright | Target | Target: $35 | Target: $40 |
| Dec 17, 2025 | Cantor Fitzgerald | Reiterate | Rating: —Target: $42 | Target: $48 |
| Dec 17, 2025 | Guggenheim | Reiterate | Rating: —Target: $35 | Target: $51 |
| Dec 15, 2025 | H.C. Wainwright | Target | Target: $16 | Target: $35 |
| Dec 14, 2025 | Cantor Fitzgerald | Target | Target: — | Target: $42 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $174.9M · Total debt $21.0M · Total assets $223.2M · Shareholders' equity $160.4M
- Revenue
- $0
- Operating income
- −$51.3M
- Net income
- −$50.4M
No dividends on record.
| Institutions | 36.36% | 21.53M ADS | |
|---|---|---|---|
| 78 holders · as of Jun 30, 2026 | |||
| Insiders | 2.68% | 1.59M ADS | |
| 6 holders · as of Jul 31, 2026 | |||
| Strategic holders | 3.60% | 2.13M ADS | |
| 1 holder · as of Apr 7, 2025 | |||
| Other | 57.36% | 33.96M ADS | |
| remainder | |||
59.21M ADS (1 ADS = 5 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (59.21M in the company's Sep 22, 2026 report, 23.92M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bioimpact Capital LLCInstitution | 6.19% | 3.67M ADS | as of Jun 30, 2026 |
Bpifrance SAStrategic10 percent owner | 3.60% | 10.67M ordinary | filed Apr 7, 2025 |
Siren, L.L.C.Institution | 3.14% | 1.86M ADS | as of Jun 30, 2026 |
Vivo Capital, LLCInstitution | 3.12% | 1.84M ADS | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 2.79% | 1.65M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 29, 2026 | Pharis Mohideen | officer: Chief Medical Officer | −464 | $2.70 |
| Jan 29, 2026 | Pharis Mohideen | officer: Chief Medical Officer | −534 | $4.86 |
| Dec 18, 2025 | Bpifrance EPIC | other: Member of 10% owner group | −1,292,103 | $4.19 |
| Dec 17, 2025 | Bpifrance EPIC | other: Member of 10% owner group | −2,076,990 | $4.85 |
| Nov 21, 2025 | Pharis Mohideen | officer: Chief Medical Officer | −1,624 | $2.77 |
- Novartis (ADR)
Xolair co-promotion in U.S. food-allergy care
- Regeneron
Systemic severe-food-allergy program in Phase 1
- ARS Pharmaceuticals
Needle-free epinephrine for food-triggered anaphylaxis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| DBV Technologies (ADR) | $12.11 | +0.09% | $289.5M | — | — | — | −53.9% |
| Novartis (ADR) | $141.16 | +0.13% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Regeneron | $804.59 | +0.80% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| ARS Pharmaceuticals | $4.43 | +1.72% | $432.0M | — | — | 3.7 | +114.2% |
| Median | 20.5 | 14.2 | 4.8 | +16.7% |